About Arthrosi
Arthrosi Therapeutics, Inc., headquartered in San Diego, California, is focused on developing AR882, a potential best-in-class, highly potent and selective next-generation URAT1 inhibitor that can be used to reduce serum uric acid levels, gout attacks and tophi in patients with gout. The gout market demand is huge and continues to grow, with approximately sri lanka telegram data 13 million patients in the United States alone, of which approximately 2 million suffer from tophaceous gout. In Phase II studies, AR882 has demonstrated encouraging efficacy and safety, and in Phase IIb studies, it showed significant results in completely clearing tophi. Currently, Arthrosi is advancing the pivotal Phase III study program for AR882.
Full Circles was founded to create novel gene editing technologies to make treatment more accessible. Its proprietary C4DNA® molecule and Tesogenase® delivery platform ensures more efficient and scalable manufacturing of gene-edited cells. The team at Full Circles consists of experts with over 10 years of experience in the CGT market and is not only passionate about curing genetic diseases, but also working to make these treatments more affordable. By developing a modular platform to achieve high delivery efficiency, Full Circles' platform has unique technical advantages over traditional viral vectors. For more information, please visit: s:ullcirclestx .